Clinicopathologic significance of expression of nuclear factor-κB RelA and its target gene products in gastric cancer patients

Table 1 Correlation of nuclear factor-κB RelA expression and clinicopathological findings n (%)

	NF-κB RelA (-)	NF-κB RelA (+)	P
Sex			1.000
Male	39 (57.4)	29 (42.6)
Female	27 (57.4)	20 (42.6)
Age (yr)			0.192
< 60	38 (63.3)	22 (36.7)
≥ 60	28 (50.9)	27 (49.1)
Site			0.002
Upper	9 (37.5)	15 (62.5)
Middle	9 (50.0)	9 (50.0)
Lower	48 (72.7)	18 (27.3)
Diffuse	0 (0)	3 (100)
Size (cm)			0.045
< 5	47 (67.1)	23 (32.9)
≥ 5	19 (46.3)	22 (53.7)
Lauren			0.988
Intestinal	27 (58.7)	19 (41.3)
Diffuse	26 (57.8)	19 (42.2)
Mixed	9 (60.0)	6 (40.0)
Differentiation			0.631
Well	11 (68.8)	5 (31.3)
Moderate	14 (50.0)	14 (50.0)
Poor	34 (60.7)	22 (39.3)
Mucinous	7 (63.6)	4 (36.4)
Lymphovascular invasion			0.012
-	44 (69.8)	19 (30.2)
+	22 (45.8)	26 (54.2)
T stage			0.012
1-2	52 (67.5)	25 (32.5)
3-4	14 (41.2)	20 (58.8)
Node			< 0.001
-	34 (81.0)	8 (19.0)
+	32 (46.4)	37 (53.6)
Lymph node ratio			< 0.001
< 0.2	60 (70.6)	25 (29.4)
≥ 0.2	6 (23.1)	20 (76.9)
Stage			< 0.001
1	36 (83.7)	7 (16.3)
2	14 (60.9)	9 (39.1)
3	16 (51.6)	15 (48.4)
4	0 (0)	18 (100)
CEA (ng/mL)			0.134
< 5	64 (59.3)	44 (40.7)
≥ 5	2 (28.6)	5 (71.4)
CA19-9 (U/mL)			< 0.001
< 37	63 (67.7)	30 (32.3)
≥ 37	3 (13.6)	19 (86.4)

NF-κB: Nuclear factor-κB; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9.